Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725758 | 1.00 | GSR (0.48) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL15641942 | 0.87 | RNPEP (0.50) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL19385944 | 0.87 | RNPEP (0.50) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL15641943 | 0.87 | RNPEP (0.50) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL181034 | 0.84 | GSR (0.52) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL4735950 | 0.84 | GSR (0.52) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL181035 | 0.84 | GSR (0.52) | GSRRNPEPCPB2GABRR1FOLH1 | |
| Lysine SCHEMBL9746892 | 0.83 | GSR (0.57) | GSRRNPEPCPB2BLM | |
| SCHEMBL18531957 | 0.82 | GSR (0.50) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL2821712 | 0.82 | GSR (0.50) | GSRRNPEPCPB2GABRR1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTH CAROLINA | 2025-01-23 | — | — | US | claimed |
| CN-103293243-B | Detection method and application of carboxy methyl lysine ingredient in food | FUJIAN INSPECTION AND RES INST FOR PRODUCT QUALITY | 2015-05-13 | — | — | CN | claimed |
| EP-4577218-A1 | NUTRACEUTICAL COMPOSITIONS AND METHODS FOR USING SAME | Mary Kay Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTH CAROLINA | 2025-01-23 | — | — | US | disclosed |
| US-20240360171-A1 | ADVANCED GLYCATION END PRODUCT ANALOGUES | PHYTOQUEST LIMITED (GB) | 2024-10-31 | — | — | US | disclosed |
| US-11970513-B2 | Advanced glycation end product analogues | PHYTOQUEST LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| WO-2024044773-A1 | NUTRACEUTICAL COMPOSITIONS AND METHODS FOR USING SAME | MARY KAY INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11903392-B2 | Hypoallergenic infant formula and methods for preparing the same | FRIESLANDCAMPINA NEDERLAND B.V. (NL) | 2024-02-20 | — | — | US | disclosed |
| US-20230048369-A1 | POLYOXAZOLINE MODIFICATIONS MITIGATE STRUCTURAL DEGENERATION OF BIOPROSTHETIC HEART VALVES | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2023-02-16 | — | — | US | disclosed |
| EP-4090323-A1 | POLYOXAZOLINE MODIFICATIONS MITIGATE STRUCTURAL DEGENERATION OF BIOPROSTHETIC HEART VALVES | The Trustees of Columbia University in the City of New York (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-4091622-A1 | COMPOSITIONS FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN | Henry Ford Health System (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20020122799-A1 | Methods for treating inflammation | TRANSTECH PHARMA, INC. | 2002-09-05 | — | — | US | disclosed |
| WO-2002050548-A1 | DETECTION OF ADVANCED GLYCATION ENDPRODUCTS IN A CEREBROSPINAL FLUID SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| EP-1217378-A1 | Detection of advanced glycation endproducts in a cerebrospinal fluid sample | Roche Diagnostics GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| US-6380165-B1 | THAT IS ANTIGENIC AND USEFUL FOR FORMING ANTIBODIES HAVING UTILITY IN STANDARDIZING DIAGNOSTIC ASSAYS, COMPRISING A LYSINE COMPONENT, AN ARGININE COMPONENT AND A REDUCING SUGAR COMPONENT | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2002-04-30 | — | — | US | disclosed |
| US-6369106-B1 | SULFHYDRYL CONTAINING COMPOUND AS ANTIOXIDANT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-04-09 | — | — | US | disclosed |
| US-20020022234-A1 | IMMUNOLOGICAL ADVANCED GLYCATION ENDPRODUCT CROSSLINK | PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2002-02-21 | — | — | US | disclosed |
| WO-2001047469-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-07-05 | — | — | WO | disclosed |
| EP-1018005-A1 | METHODS FOR MEASURING AND ELIMINATING ADVANCED GLYCATION ENDPRODUCTS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999014587-A1 | METHODS FOR MEASURING AND ELIMINATING ADVANCED GLYCATION ENDPRODUCTS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970513-B2 | Advanced glycation end product analogues | AGER, SI, GALE | GSR 774/4885RNPEP 170/4885CPB2 2414/4885 |
| US-20240360171-A1 | ADVANCED GLYCATION END PRODUCT ANALOGUES | AGER, GALE, SI | GSR 727/4885RNPEP 175/4885CPB2 2613/4885 |
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | L1CAM, CD274, PDCD1LG2 | GSR 592/4885RNPEP 1788/4885CPB2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.